#ACR22 Appraisal, Praise & Critique Dr. Cush talks ACR22, the highs and the lows. https://t.co/NoRqvFaBKl https://t.co/0b5IlAojVq

Exciting Data for SLE: Plenaries from #ACR22 Dr. Michael Putman ( @EBRheum ) shares SLE updates shared at #ACR22. https://t.co/e6tCwLdHMS https://t.co/u7yoE4T9Zs

Dual target blockade may be better than one in SLE Dr. Yusof ( @Yuz6Yusof) discusses abstracts #L07 and #1001 presented at #ACR22. https://t.co/0SzQAorzZy https://t.co/fZ6CpFNSWI

Lupus Topic Panel Join RheumNow to recap the best and most interesting data presented at #ACR22 in the area of SLE. Panelists: @KDAO2011 @bella_mehta @Yuz6Yusof @ericdeinmd @EBRheum @RHEUMarampa @Janetbirdope https://t.co/7oUZcQK27U https://t.co/1JClivUJpk

2022 ACR/EULAR Classification Criteria for GCA Dr. Michael Putman discusses interesting take-home messages from the Vasculitis Investigators Meeting at ACR22 Convergence regarding the 2022 ACR/EULAR Classification Criteria for GCA. https://t.co/FL9FGhWcxB https://t.co/JKi7Nn4O2O

Avoid Abatacept in RA patients with a history of cancer? Dr. Richard Conway ( @RichardPAConway ) discusses abstracts #0267 and #0255 presented at #ACR22. https://t.co/1lC33XlBt7 https://t.co/ttUQaTVF43